The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Treatments for spasticity and pain in multiple sclerosis: a systematic review
Open accessAbstract
OBJECTIVES: To identify the drug treatments currently available for the management of spasticity and pain in multiple sclerosis (MS), and to evaluate their clinical and cost-effectiveness. DATA SOURCES: Electronic bibliographic databases, National Research Register, MRC Clinical Trials Register and the US National Institutes of Health Clinical Trials Register. REVIEW METHODS: Systematic searches identified 15 interventions for the treatment of spasticity and 15 interventions for treatment of pain. The quality and outcomes of the studies were evaluated. Reviews of the treatment of spasticity and pain when due to other aetiologies were also sought. RESULTS: There is limited evidence of the effectiveness of four oral drugs for spasticity: baclofen, dantrolene, diazepam and tizanidine. Tizanidine appears to be no more effective than comparator drugs such as baclofen and has a slightly different side-effects profile. Despite claims that it causes less muscle weakness, there was very little evidence that tizanidine performed any better in this respect than other drugs, although it is more expensive. The findings of this review are consistent with reviews of the same treatments for spasticity derived from other aetiologies. There is good evidence that both botulinum toxin (BT) and intrathecal baclofen are effective in reducing spasticity, and both are associated with functional benefit. However, they are invasive, and substantially more expensive. None of the studies included in the review of pain were designed specifically to evaluate the alleviation of pain in patients with MS and there was no consistency regarding the use of validated outcome measures. It was suggested that, although expensive, the use of intrathecal baclofen may be associated with significant savings in hospitalisation costs in relation to bed-bound patients who are at risk of developing pressure sores, thus enhancing its cost-effectiveness. No studies of cost-effectiveness were identified in the review of pain. There is evidence, albeit limited, of the clinical effectiveness of baclofen, dantrolene, diazepam, tizanidine, intrathecal baclofen and BT and of the potential cost-effectiveness of intrathecal baclofen in the treatment of spasticity in MS. CONCLUSIONS: Many of the interventions identified are not licensed for the alleviation of pain or spasticity in MS and the lack of evidence relating to their effectiveness may also limit their widespread use. Indeed, forthcoming information relating to the use of cannabinoids in MS may result in there being better evidence of the effectiveness of new treatments than of any of the currently used drugs. It may therefore be of value to carry out double-blind randomised controlled trials of interventions used in current practice, where outcomes could include functional benefit and impact on quality of life. Further research into the development and validation of outcomes measures for pain and spasticity may also be useful, as perhaps would cost-utility studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,424
The Sickness Impact Profile: Development and Final Revision of a Health Status Measure
Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S. (1981) · Medical Care · doi:10.1097/00005650-198108000-00001 · Cited by 4,619
PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.
Ashworth, B. (1964) · PubMed · Cited by 1,475
A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
Beck, R. W., Cleary, P. A., Anderson, M. M., Keltner, J. L., Shults, W. T., Kaufman, D. I., Buckley, E. G., Corbett, J. J., Kupersmith, M. J., Miller, N. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202273260901 · Cited by 1,355
Intrathecal Baclofen for Severe Spinal Spasticity
Penn, R. D., Savoy, S. M., Corcos, D., Latash, M., Gottlieb, G., Parke, B., & Kroin, J. S. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906083202303 · Cited by 754
Treatment of spasticity with botulinum toxin: A double‐blind study
Snow, B. J., Tsui, J. K. C., Bhatt, M. H., Varelas, M., Hashimoto, S. A., & Calne, D. B. (1990) · Annals of Neurology · doi:10.1002/ana.410280407 · Cited by 414
Baclofen in the treatment of trigeminal neuralgia: Double‐blind study and long‐term follow‐up
Fromm, G. H., Terrence, C. F., & Chattha, A. S. (1984) · Annals of Neurology · doi:10.1002/ana.410150306 · Cited by 368
CONTINUOUS INTRATHECAL BACLOFEN FOR SEVERE SPASTICITY
PENN, R. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90228-4 · Cited by 308
Intrathecal baclofen for spasticity of spinal origin: seven years of experience
Penn, R. D. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.77.2.0236 · Cited by 279
Anti-spasticity agents for multiple sclerosis
Shakespeare, D., Boggild, M., & Young, C. A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001332 · Cited by 271
Hyman, N. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.707 · Cited by 248
Trigeminal neuralgia in multiple sclerosis
Hooge, J. P., & Redekop, W. K. (1995) · Neurology · doi:10.1212/wnl.45.7.1294 · Cited by 229
Pain syndromes in multiple sclerosis
Moulin, D. E., Foley, K. M., & Ebers, G. C. (1988) · Neurology · doi:10.1212/wnl.38.12.1830 · Cited by 224
Ebers, G. C. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530240016003 · Cited by 216
Anticonvulsant Drugs and Chronic Pain
Swerdlow, M. (1984) · Clinical Neuropharmacology · doi:10.1097/00002826-198403000-00003 · Cited by 208
Botulinum toxin A for spasticity, muscle spasms, and rigidity
Grazko, M. A., Polo, K. B., & Jabbari, B. (1995) · Neurology · doi:10.1212/wnl.45.4.712 · Cited by 207
Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients
Archibald, C. J., McGrath, P. J., Ritvo, P. G., Fisk, J. D., Bhan, V., Maxner, C. E., & Murray, T. J. (1994) · Pain · doi:10.1016/0304-3959(94)90188-0 · Cited by 206
Haas, B. M., Bergström, E., Jamous, A., & Bennie, A. (1996) · Spinal Cord · doi:10.1038/sc.1996.100 · Cited by 203
Clifford, D. B., & Trotter, J. L. (1984) · Archives of Neurology · doi:10.1001/archneur.1984.04050230052017 · Cited by 193
Acute and chronic pain syndromes in multiple sclerosis
Stenager, E., Knudsen, L., & Jensen, K. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb04937.x · Cited by 187
Richards, R. G., Sampson, F. C., Beard, S. M., & Tappenden, P. (2002) · Health Technology Assessment · doi:10.3310/hta6100 · Cited by 173
Self-citationGabapentin relieves trigeminal neuralgia in multiple sclerosis patients
Khan, O. A. (1998) · Neurology · doi:10.1212/wnl.51.2.611 · Cited by 162
Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial
Cutter, N. C., Scott, D. D., Johnson, J. C., & Whiteneck, G. (2000) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(00)90135-7 · Cited by 160
Bornstein, M. (1986) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198603000-00012 · Cited by 160
Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity
Rae-Grant, A. D., Eckert, N. J., Bartz, S., & Reed, J. F. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500307 · Cited by 159
The Ashworth Scale: A Reliable and Reproducible Method of Measuring Spasticity
Lee, K.-H., Carson, L., Kinnin, E., & Patterson, V. (1989) · Neurorehabilitation and neural repair · doi:10.1177/136140968900300406 · Cited by 125
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis
Mueller, M. E., Gruenthal, M., Olson, W. L., & Olson, W. H. (1997) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(97)90168-4 · Cited by 121
Baclofen in the Treatment of Spasticity
Hudgson, P., & Weightman, D. (1971) · BMJ · doi:10.1136/bmj.4.5778.15 · Cited by 121
Effect of treatment with botulinum toxin on spasticity
Das, T. K., & Park, D. M. (1989) · Postgraduate Medical Journal · doi:10.1136/pgmj.65.762.208 · Cited by 117
Open label gabapentin treatment for pain in multiple sclerosis
Houtchens, M. K., Richert, J. R., Sami, A., & ROSE, J. W. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300407 · Cited by 116
An open-lebel trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients
Solaro, C. M., Lunardi, G. L., Capello, E., Inglese, M., Uccelli, M. M., Uccelli, A., & Mancardi, G. (1998) · Neurology · doi:10.1212/wnl.51.2.609 · Cited by 111
Sakurai, M., & Kanazawa, I. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00322-0 · Cited by 109
Nance, P. W., Schryvers, O. I., Schmidt, B. J., et al. (1995) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100040452 · Cited by 105
Sachais, B. A. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500190056008 · Cited by 105
Solaro, C. M., Uccelli, M. M., Uccelli, A., Leandri, M., & Mancardi, G. (2000) · European Neurology · doi:10.1159/000008192 · Cited by 100
Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study
Stenager, E., Knudsen, L., & Jensen, K. B. (1995) · Neurological Sciences · doi:10.1007/bf02230913 · Cited by 98
Pharmacological interventions for spasticity following spinal cord injury
Taricco, M., Adone, R., Pagliacci, C., & Telaro, E. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001131 · Cited by 93
Glossopharyngeal neuralgia and MS
Minagar, A., & Sheremata, W. A. (2000) · Neurology · doi:10.1212/wnl.54.6.1368 · Cited by 93
Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis
Bass, B., Weinshenker, B. G., Rice, G. P., et al. (1988) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100027104 · Cited by 90
Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue
Reder, A. T., & Amason, B. G. W. (1995) · Neurology · doi:10.1212/wnl.45.6.1097 · Cited by 85
A comparison of baclofen and diazepam in the treatment of spasticity
Cartlidge, N. E. F., Hudgson, P., & Weightman, D. (1974) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(74)90137-3 · Cited by 82
Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis
Leandri, M., Lunardi, G., Inglese, M., Messmer-Uccelli, M. X. E. L., Mancardi, G., Gottlieb, A., & Solaro, C. M. (2000) · Journal of Neurology · doi:10.1007/s004150070157 · Cited by 79
Chronic and acute pain syndromes in patients with multiple sclerosis.
Indaco, A., Iachetta, C., Nappi, C., Socci, L., & Pb, C. (1994) · PubMed · Cited by 77
Smith, C. R., Birnbaum, G., Carter, J. L., et al. (1994) · PubMed · Cited by 75
Stien, R., Nordal, H. J., Oftedal, S., et al. (1987) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1987.tb07916.x · Cited by 72
Nance, P. W., Sheremata, W. A., LYNCH, S. G., Vollmer, T., Hudson, S., Francis, G., O'Connor, P. W., Cohen, J. A., Schapiro, R. T., Whitham, R. H., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550180049011 · Cited by 72
Pain in multiple sclerosis patients
Vermote, R., Ketelaer, P., & Carton, H. (1986) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(86)80002-6 · Cited by 71
Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients
Hoogstraten, M. C., Ploeg, R. J., van den Burg, W., Vreeling, A., van Marle, S., & Minderhoud, J. M. (1988) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1988.tb05899.x · Cited by 71
Treatment of Spasticity with Tizanidine in Multiple Sclerosis
Lapierre, Y., Bouchard, S., Tansey, C. M., et al. (1987) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100038026 · Cited by 70
Hohol, M. J., Olek, M. J., Orav, E. J., Stazzone, L., Hafler, D. A., Khoury, S. J., Dawson, D. M., & Weiner, H. L. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500i606 · Cited by 69
Drug points: Worsening of symptoms of multiple sclerosis associated with carbamazepine
Ramsaransing, G. S. M. (2000) · BMJ · doi:10.1136/bmj.320.7242.1113 · Cited by 66
The pain experience of a multiple sclerosis population: a descriptive study.
Warnell, P. (1991) · PubMed · Cited by 65
Tizanidine in the treatment of spasticity
Newman, P. M., Nogués, M. A., Newman, P. K., et al. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf01061374 · Cited by 64
A DOUBLE-BLIND TRIAL WITH BACLOFEN (LIORESAL®) AND DIAZEPAM IN SPASTICITY DUE TO MULTIPLE SCLEROSIS
From, A., & Heltberg, A. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1975.tb01366.x · Cited by 63
PAIN IN CENTRAL AND PERIPHERAL DEMYELINATING DISORDERS
Moulin, D. E. (1998) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70103-1 · Cited by 63
Comparison of dantrolene sodium and diazepam in the treatment of spasticity.
Schmidt, R. T., Lee, R. H., & Spehlmann, R. (1976) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.39.4.350 · Cited by 61
The Disability Status Scale for multiple sclerosis
Kurtzke, J. F. (1989) · Neurology · doi:10.1212/wnl.39.2.291 · Cited by 60
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin
Samkoff, L., Daras, M. D., Tuchman, A. J., et al. (1997) · Neurology · doi:10.1212/wnl.49.1.304 · Cited by 57
The effect of dantrolene sodium on spasticity in multiple sclerosis
Gelenberg, A. J., & Poskanzer, D. C. (1973) · Neurology · doi:10.1212/wnl.23.12.1313 · Cited by 56
Eyssette, M., Rohmer, F., Serratrice, G., et al. (1988) · Current Medical Research and Opinion · doi:10.1185/03007998809111121 · Cited by 56
Action of cyproheptadine in spastic paraparetic patients.
Barbeau, H., Richards, C. L., & Bédard, P. J. (1982) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.45.10.923 · Cited by 54
Smolenski, C., Muff, S., & Smolenski-Kautz, S. (1981) · PubMed · Cited by 52
Intrathecal Baclofen for Severe Spinal Spasticity
Penn, R. D., Savoy, S. M., Corcos, D. M., Latash, M. L., Gottlieb, G. L., Parke, B., & Kroin, J. S. (1990) · Survey of Anesthesiology · doi:10.1097/00132586-199002000-00029 · Cited by 52
TREATMENT OF ACQUIRED MUSCLE SPASTICITY USING PHENOL PERIPHERAL NERVE BLOCKS
Botte, M. J., Abrams, R. A., & Bodine, S. C. (1995) · Orthopedics · doi:10.3928/0147-7447-19950201-14 · Cited by 50
Multiple sclerosis: Symptomatic treatment
Thompson, A. J. (1996) · Journal of Neurology · doi:10.1007/bf00900942 · Cited by 50
Pain in chronic multiple sclerosis
Kassirer, M., & Osterberg, D. H. (1987) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(87)80022-2 · Cited by 50
The Use of Baclofen in Treatment of Spasticity in Multiple Sclerosis
Sawa, G. M., & Paty, D. W. (1979) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100023994 · Cited by 47
Hohol, M. J., Olek, M. J., Orav, E. J., Stazzone, L., Hafler, D. A., Khoury, S. J., Dawson, D. M., & Weiner, H. L. (1999) · Multiple Sclerosis Journal · doi:10.1191/135245899678846492 · Cited by 44
Roussan, M. S., Terrence, C. F., & Fromm, G. H. (1985) · PubMed · Cited by 42
Symptomatic treatment in multiple sclerosis
Thompson, A. J. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199808000-00005 · Cited by 39
An Antispasticity Effect of Threonine in Multiple Sclerosis
Hauser, S. L., Doolittle, T. H., Lopez-Bresnahan, M. V., Shahani, B. T., Schoenfeld, D., Shih, V. E., Growdon, J. H., & Lehrich, J. R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530330045014 · Cited by 38
Moulin, D. E. (1989) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30816-8 · Cited by 38
The incidence and mortality of multiple sclerosis in south east Wales.
Hennessy, A., Swingler, R. J., & Compston, D. A. S. (1989) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.9.1085 · Cited by 37
Lamotrigine adjunctive therapy in painful phenomena in MS: Preliminary observations
Cianchetti, C., Zuddas, A., Randazzo, A. P., Perra, L., & Marrosu, M. G. (1999) · Neurology · doi:10.1212/wnl.53.2.433 · Cited by 36
GABAPENTIN FOR RELIEF OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS1
Dunevsky, A., & Perel, A. B. (1998) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199809000-00020 · Cited by 32
Jerusalem, F. (1968) · PubMed · Cited by 28
Treatment of Pain in Multiple Sclerosis — Preliminary Report
Albert, M. L. (1969) · New England Journal of Medicine · doi:10.1056/nejm196906192802509 · Cited by 27
Lioresal (baclofen) treatment of spasticity in multiple sclerosis.
Jv, B. (1975) · PubMed · Cited by 16
Levine, I. M., Jossmann, P. B., & DeAngelis, V. (1977) · PubMed · Cited by 14
Letter: Treatment of spasticity in multiple sclerosis with dantrolene
Tolosa, E. S. (1975) · JAMA · doi:10.1001/jama.233.10.1046b · Cited by 11
Diazepam in the Relief of Muscle Spasm Resulting from Spinal-Cord Lesions
Neill, R. W. K. (1964) · Lara D. Veeken · doi:10.1093/rheumatology/vii.suppl_1.33 · Cited by 10
Cited by
Hobart, J., & Cano, S. (2009) · Health Technology Assessment · doi:10.3310/hta13120 · Cited by 621
Prevalence and treatment of spasticity reported by multiple sclerosis patients
Rizzo, M. A., Hadjimichael, O. C., Preiningerova, J., & Vollmer, T. L. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1085oa · Cited by 552
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Pain associated with multiple sclerosis: Systematic review and proposed classification
O’Connor, A. B., Schwid, S. R., Herrmann, D. N., Markman, J. D., & Dworkin, R. H. (2008) · Pain · doi:10.1016/j.pain.2007.08.024 · Cited by 498
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Metadata
- Authors
- Beard, S., Hunn, A., & Wight, J.
- Venue
- Health Technology Assessment
- Published
- 2003-12
- Volume
- 7
- Issue
- 40
- Pages
- iii, ix-x, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2168300234
- Cited by
- 266
- References
- 82
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.